Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California, USA.
J Am Geriatr Soc. 2022 Jan;70(1):168-177. doi: 10.1111/jgs.17508. Epub 2021 Oct 19.
Central nervous system (CNS)-active medication use is an important modifiable risk factor for falls in older adults. A fall-related injury should prompt providers to evaluate and reduce CNS-active medications to prevent recurrent falls. We evaluated change in CNS-active medications up to 12 months following a fall-related injury in community-dwelling older adults compared with a matched cohort without fall-related injury.
Participants were from the Adult Changes in Thought study conducted at Kaiser Permanente Washington. Fall-related injury codes between 1994 and 2014 defined index encounters in participants with no evidence of such injuries in the preceding year. We matched each fall-related injury index encounter with up to five randomly selected clinical encounters from participants without injury. Using automated pharmacy data, we estimated the average change in CNS-active medication use at 3, 6, and 12 months post-index according to the presence or absence of CNS-active medication use before index.
One thousand five hundred sixteen participants with fall-related injury index encounters (449 CNS-active users, 1067 nonusers) were matched to 7014 index encounters from people without fall-related injuries (1751 users, 5236 nonusers). Among CNS-active users at the index encounter, those with fall-related injury had an average decrease in standard daily doses (SDDs) at 12 months (-0.43; 95% CI: -0.63 to -0.23), and those without injury had a greater (p = 0.047) average decrease (-0.66; 95% CI: -0.78 to -0.55). Among nonusers at index, those with fall-related injury had a smaller increase than those without injury (+0.17, 95% CI: +0.13 to +0.21, vs. +0.24, 95% CI: +0.20 to +0.28, p = 0.005).
The differences in CNS-active medication use change over 12 months between those with and without fall-related injury were small and unlikely to be clinically significant. These results suggest that fall risk-increasing drug use is not reduced following a fall-related injury, thus opportunities exist to reduce CNS-active medications, a potentially modifiable risk factor for falls.
中枢神经系统(CNS)活性药物的使用是老年人跌倒的一个重要可改变的危险因素。跌倒相关损伤应促使医务人员评估和减少 CNS 活性药物,以防止再次跌倒。我们评估了与跌倒相关损伤后 12 个月内社区居住的老年人中 CNS 活性药物的变化,与无跌倒相关损伤的匹配队列进行比较。
参与者来自 Kaiser Permanente Washington 进行的成人思维变化研究。1994 年至 2014 年期间的跌倒相关损伤代码定义了参与者的索引事件,这些参与者在前一年没有此类损伤的证据。我们将每个与跌倒相关的损伤索引事件与从无损伤参与者中随机选择的五个临床事件进行匹配。使用自动化药房数据,根据索引前是否使用 CNS 活性药物,估计索引后 3、6 和 12 个月时 CNS 活性药物使用的平均变化。
1516 名与跌倒相关的损伤索引事件(449 名 CNS 活性药物使用者,1067 名非使用者)与 7014 名无跌倒相关损伤的索引事件(1751 名使用者,5236 名非使用者)相匹配。在索引时使用 CNS 活性药物的患者中,跌倒相关损伤患者的标准日剂量(SDD)在 12 个月时平均减少(-0.43;95%CI:-0.63 至-0.23),而无损伤患者的平均减少量更大(p=0.047)(-0.66;95%CI:-0.78 至-0.55)。在索引时非使用者中,跌倒相关损伤患者的增加量小于无损伤患者(+0.17,95%CI:+0.13 至+0.21,vs.+0.24,95%CI:+0.20 至+0.28,p=0.005)。
在有跌倒相关损伤和无跌倒相关损伤的患者中,12 个月内 CNS 活性药物使用变化的差异较小,且不太可能具有临床意义。这些结果表明,跌倒风险增加的药物使用并未在跌倒相关损伤后减少,因此有机会减少 CNS 活性药物,这是跌倒的一个潜在可改变的危险因素。